CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 551 enrolled
Drug / intervention
Azilsartan medoxomil and chlorthalidone +2 moredrug
Likely dose
Azilsartan medoxomil and chlorthalidone 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00591773
NCT00591773Phase 3Completed
CompareCT.gov

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 When Co-administered With Chlorthalidone in Subjects With Essential Hypertension

Takeda·interventional·Posted Jan 11, 2008·Updated Apr 19, 2011

In Brief

A Phase 3 clinical trial evaluating Azilsartan medoxomil and chlorthalidone and Chlorthalidone for Hypertension. Completed, enrolled 551 participants across 46 sites.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with chlorthalidone in treating individuals with essential hypertension, compared to treatment with chlorthalidone alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 11, 2008
Enrollment StartSep 1, 2007
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 18.5 years ago

Interventions

Azilsartan medoxomil and chlorthalidonedrug

Azilsartan medoxomil 40 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily; and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.

Azilsartan medoxomil and chlorthalidonedrug

Azilsartan medoxomil 80 mg, tablets, orally, once daily; azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.

Chlorthalidonedrug

Chlorthalidone 25 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily and azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.